BIOCERES CROP SOLUTIONS CORP (BIOX) Stock Fundamental Analysis
NASDAQ:BIOX - Nasdaq - KYG1117K1141 - Common Stock
We assign a fundamental rating of 3 out of 10 to BIOX. BIOX was compared to 85 industry peers in the Chemicals industry. BIOX may be in some trouble as it scores bad on both profitability and health. BIOX has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
BIOX had positive earnings in the past year.
BIOX had a positive operating cash flow in the past year.
In multiple years BIOX reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: BIOX reported negative operating cash flow in multiple years.
1.2 Ratios
BIOX has a worse Return On Assets (0.38%) than 61.45% of its industry peers.
BIOX's Return On Equity of 1.03% is on the low side compared to the rest of the industry. BIOX is outperformed by 60.24% of its industry peers.
BIOX has a Return On Invested Capital (5.17%) which is in line with its industry peers.
The Average Return On Invested Capital over the past 3 years for BIOX is in line with the industry average of 6.59%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.38% | ||
| ROE | 1.03% | ||
| ROIC | 5.17% |
ROA(3y)0.43%
ROA(5y)0.14%
ROE(3y)0.56%
ROE(5y)-0.23%
ROIC(3y)6.06%
ROIC(5y)8.13%
1.3 Margins
Looking at the Profit Margin, with a value of 0.70%, BIOX is doing worse than 61.45% of the companies in the same industry.
Looking at the Operating Margin, with a value of 9.29%, BIOX is in line with its industry, outperforming 53.01% of the companies in the same industry.
BIOX's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 40.15%, BIOX belongs to the top of the industry, outperforming 80.72% of the companies in the same industry.
BIOX's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.29% | ||
| PM (TTM) | 0.7% | ||
| GM | 40.15% |
OM growth 3Y-17.81%
OM growth 5Y-13.52%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.98%
GM growth 5Y-2.6%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BIOX is destroying value.
The number of shares outstanding for BIOX remains at a similar level compared to 1 year ago.
Compared to 5 years ago, BIOX has more shares outstanding
BIOX has a worse debt/assets ratio than last year.
2.2 Solvency
BIOX has a debt to FCF ratio of 14.33. This is a negative value and a sign of low solvency as BIOX would need 14.33 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 14.33, BIOX is in line with its industry, outperforming 45.78% of the companies in the same industry.
BIOX has a Debt/Equity ratio of 0.42. This is a healthy value indicating a solid balance between debt and equity.
BIOX's Debt to Equity ratio of 0.42 is fine compared to the rest of the industry. BIOX outperforms 66.27% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.42 | ||
| Debt/FCF | 14.33 | ||
| Altman-Z | N/A |
ROIC/WACC0.61
WACC8.46%
2.3 Liquidity
BIOX has a Current Ratio of 1.24. This is a normal value and indicates that BIOX is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.24, BIOX is not doing good in the industry: 86.75% of the companies in the same industry are doing better.
BIOX has a Quick Ratio of 1.24. This is a bad value and indicates that BIOX is not financially healthy enough and could expect problems in meeting its short term obligations.
BIOX's Quick ratio of 0.86 is on the low side compared to the rest of the industry. BIOX is outperformed by 75.90% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.24 | ||
| Quick Ratio | 0.86 |
3. Growth
3.1 Past
The earnings per share for BIOX have decreased strongly by -77.06% in the last year.
BIOX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.04%.
The Revenue has been growing by 23.73% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-77.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.57%
Revenue 1Y (TTM)9.04%
Revenue growth 3Y31.01%
Revenue growth 5Y23.73%
Sales Q2Q%-20.58%
3.2 Future
BIOX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 83.09% yearly.
Based on estimates for the next years, BIOX will show a small growth in Revenue. The Revenue will grow by 7.98% on average per year.
EPS Next Y337.96%
EPS Next 2Y156.31%
EPS Next 3Y144.94%
EPS Next 5Y83.09%
Revenue Next Year-1.36%
Revenue Next 2Y4.42%
Revenue Next 3Y6.27%
Revenue Next 5Y7.98%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
BIOX is valuated quite expensively with a Price/Earnings ratio of 172.25.
69.88% of the companies in the same industry are cheaper than BIOX, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 27.96, BIOX is valued quite expensively.
A Price/Forward Earnings ratio of 17.78 indicates a rather expensive valuation of BIOX.
BIOX's Price/Forward Earnings ratio is in line with the industry average.
When comparing the Price/Forward Earnings ratio of BIOX to the average of the S&P500 Index (24.11), we can say BIOX is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 172.25 | ||
| Fwd PE | 17.78 |
4.2 Price Multiples
BIOX's Enterprise Value to EBITDA ratio is in line with the industry average.
Based on the Price/Free Cash Flow ratio, BIOX is valued a bit cheaper than the industry average as 61.45% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 22.91 | ||
| EV/EBITDA | 9.87 |
4.3 Compensation for Growth
BIOX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as BIOX's earnings are expected to grow with 144.94% in the coming years.
PEG (NY)0.51
PEG (5Y)N/A
EPS Next 2Y156.31%
EPS Next 3Y144.94%
5. Dividend
5.1 Amount
BIOX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIOCERES CROP SOLUTIONS CORP
NASDAQ:BIOX (1/17/2025, 8:00:00 PM)
After market: 6.89 0 (0%)6.89
-0.02 (-0.29%)
Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)
Earnings (Next)
Inst Owners22.3%
Inst Owner Change-0.48%
Ins Owners1.68%
Ins Owner ChangeN/A
Market Cap433.04M
Analysts83.64
Price Target13.77 (99.85%)
Short Float %2.21%
Short Ratio3.59
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP5.39%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-65.66%
Min EPS beat(2)-112.05%
Max EPS beat(2)-19.26%
EPS beat(4)0
Avg EPS beat(4)-107.6%
Min EPS beat(4)-219.35%
Max EPS beat(4)-19.26%
EPS beat(8)1
Avg EPS beat(8)89.23%
EPS beat(12)2
Avg EPS beat(12)36.14%
EPS beat(16)3
Avg EPS beat(16)-2.99%
Revenue beat(2)0
Avg Revenue beat(2)-13.29%
Min Revenue beat(2)-16.39%
Max Revenue beat(2)-10.19%
Revenue beat(4)1
Avg Revenue beat(4)-4.19%
Min Revenue beat(4)-16.39%
Max Revenue beat(4)17.49%
Revenue beat(8)3
Avg Revenue beat(8)4.11%
Revenue beat(12)7
Avg Revenue beat(12)12.07%
Revenue beat(16)10
Avg Revenue beat(16)12%
PT rev (1m)0%
PT rev (3m)-8.16%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-108.57%
EPS NY rev (1m)0%
EPS NY rev (3m)-69.33%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-9.56%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-7.44%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 172.25 | ||
| Fwd PE | 17.78 | ||
| P/S | 0.93 | ||
| P/FCF | 22.91 | ||
| P/OCF | 10.39 | ||
| P/B | 1.38 | ||
| P/tB | 16.11 | ||
| EV/EBITDA | 9.87 |
EPS(TTM)0.04
EY0.58%
EPS(NY)0.39
Fwd EY5.63%
FCF(TTM)0.3
FCFY4.37%
OCF(TTM)0.66
OCFY9.63%
SpS7.4
BVpS5
TBVpS0.43
PEG (NY)0.51
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.38% | ||
| ROE | 1.03% | ||
| ROCE | 8.29% | ||
| ROIC | 5.17% | ||
| ROICexc | 5.79% | ||
| ROICexgc | 15.12% | ||
| OM | 9.29% | ||
| PM (TTM) | 0.7% | ||
| GM | 40.15% | ||
| FCFM | 4.07% |
ROA(3y)0.43%
ROA(5y)0.14%
ROE(3y)0.56%
ROE(5y)-0.23%
ROIC(3y)6.06%
ROIC(5y)8.13%
ROICexc(3y)6.87%
ROICexc(5y)10.39%
ROICexgc(3y)15.77%
ROICexgc(5y)22.76%
ROCE(3y)9.78%
ROCE(5y)13.22%
ROICexcg growth 3Y-15.22%
ROICexcg growth 5Y-15.76%
ROICexc growth 3Y-21.1%
ROICexc growth 5Y-17.96%
OM growth 3Y-17.81%
OM growth 5Y-13.52%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.98%
GM growth 5Y-2.6%
F-Score6
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.42 | ||
| Debt/FCF | 14.33 | ||
| Debt/EBITDA | 2.03 | ||
| Cap/Depr | 106.98% | ||
| Cap/Sales | 4.9% | ||
| Interest Coverage | 1.75 | ||
| Cash Conversion | 64.63% | ||
| Profit Quality | 582.8% | ||
| Current Ratio | 1.24 | ||
| Quick Ratio | 0.86 | ||
| Altman-Z | N/A |
F-Score6
WACC8.46%
ROIC/WACC0.61
Cap/Depr(3y)107.09%
Cap/Depr(5y)127.69%
Cap/Sales(3y)4.36%
Cap/Sales(5y)4.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-77.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.57%
EPS Next Y337.96%
EPS Next 2Y156.31%
EPS Next 3Y144.94%
EPS Next 5Y83.09%
Revenue 1Y (TTM)9.04%
Revenue growth 3Y31.01%
Revenue growth 5Y23.73%
Sales Q2Q%-20.58%
Revenue Next Year-1.36%
Revenue Next 2Y4.42%
Revenue Next 3Y6.27%
Revenue Next 5Y7.98%
EBIT growth 1Y-17.6%
EBIT growth 3Y7.68%
EBIT growth 5Y7%
EBIT Next Year31.21%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y194.63%
FCF growth 3YN/A
FCF growth 5Y-6.35%
OCF growth 1Y1510.2%
OCF growth 3YN/A
OCF growth 5Y7.02%